08:28:05 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2023
2023-11-13 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 Årsstämma 2023
2023-03-24 Extra Bolagsstämma 2022
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2021-03-31 08:00:00

Ahead of the Annual General Meeting of Qlife Holding AB on May 5, 2021, the Company's Nomination Committee announces its proposal regarding board members and chair of the board.

Qlife's Nomination Committee proposes that the Annual General Meeting elects Mette-Marie Harild, Ulrik Harrysson and Mikael Persson as new Board members.

Mette-Marie Harild, born 1958, has a long experience of leading international organizations within the pharma/medical industry, inter alia from Medtronic where she worked for many years, most recently as Regional Vice President ABGI & Nordic. In her career, Mette-Marie has had a strong focus on customers, sales and change management and has vast experiences of public/private cooperation and purchases. Mette-Marie is originally a trained dentist and has an Executive MBA in Change Management. Mette-Marie is chairman of AmCham Healthcare Committee and the Danish Chamber of Commerce Life Science Board and is a member of the Danish Chamber of Commerce, Neurescue and the Danish Business Development Board under the Ministry of Commerce (Danish Erhvervsfremmebestyrelse). Shares in Qlife: 0.

Ulrik Harrysson, born 1969, is a driven strategist with many years' experience of business development and sales in growth companies such as SyntheticMR, Hermes Medical Solutions and HemoCue, today as CEO of SyntheticMR. Ulrik has a deep experience of building sales organizations, through subsidiaries and distributor cooperations, industrial cooperation agreements, international product launches and tenders. Ulrik holds a Master of Science in Business Administration and has participated in several leadership programs. Shares in Qlife: 2000.

Mikael Persson, born 1967, has extensive operational and strategic global experience for instance as EVP and COO of Arjo, Getinge and Flügger, today as EVP Supply Chain, Operations and Product Development at Arjo. Mikael has through his career had the responsibility for manufacturing and purchases throughout the world and has received extensive experiences of purchase and manufacturing agreements, process optimization and rebuilding of Supply chain. Mikael holds a Master in Mechanical Engineering. Shares in Qlife: 0.

The Nomination Committee proposes the re-election of Mette Gross, John Moll, Niklas Marschall and Thomas Warthoe. Mette Gross is proposed re-elected as Chair of the Board.

The proposed board of directors is, with regard to the Company's activities and stage of development, considered an adequate board composition in relation to qualifications, experience and background of the proposed board members. The Nomination Committee therefore considers that the proposed composition with seven board members is adequate to meet the needs which the Company's operations are facing and will be facing.

The Nomination Committee's complete proposal and motivational statement will be presented in connection with the notice convening the Annual General Meeting.